Stocksigma LogoStocksigma Logo

Glenmark Receives U.S. FDA EIR with VAI Status for Goa Facility

Glenmark Pharmaceuticals Ltd announced on 23rd Sep'26 that it received the Establishment Inspection Report (EIR) from the U.S

Glenmark Receives U.S. FDA EIR with VAI Status for Goa Facility

Glenmark Pharmaceuticals Ltd 路 Press Release 路 23 Sept 2026, 2:16 pm

Glenmark Receives U.S. FDA EIR with VAI Status for Goa Facility Glenmark Pharmaceuticals Ltd announced on 23rd Sep'26 that it received the Establishment Inspection Report (EIR) from the U.S. FDA for its formulations manufacturing facility in Goa, India. The regulator classified the inspection outcome as Voluntary Action Indicated (VAI), successfully closing the audit conducted between 22nd Jun'26 and 30th Jun'26.

Original exchange filing (PDF)

More announcements from Glenmark Pharmaceuticals Ltd

All Glenmark Pharmaceuticals Ltd announcements